Catherine Dunand brings her expertise in healthcare technological innovation to support Diabeloop’s growth and international development.
The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.83 per common share, payable on March 31, 2021 to holders of record on March 10, 2021. The indicated annual dividend rate is $3.32 per share.
Brighter has now received the outstanding approval of consumables connected to the Actiste service from the SFDA (Saudi Food and Drug Authority) in Saudi Arabia. The approval process with the country's telecommunications authority (CITC) regarding cellular connectivity is still ongoing.
#insulin pen
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced Tom Polen, BD CEO and president, will assume additional responsibility as chairman of the BD board of directors, effective April 28, 2021.
Never before has it been so important to help share awareness of the signs of type 1 diabetes in our communities. DigiBete and Diabetes UK have some useful resources that you can use and share.
The board of Brighter AB (publ) has decided to wind down the financing cooperation with Unwrap Finance, which formed one of the main pillars in the financing of the company's ongoing operations and was referred to in the financial reporting, to instead focus on other financing solutions going forward.
Today announces the appointment of Jay L. Warner, a 30-year veteran of the healthcare industry, as head of U.S. commercial operations.
Mining knowledge from continuous glucose monitoring (CGM) data to classify highly heterogeneous patients with type 2 diabetes according to their characteristics remains unaddressed. A refined clustering method that retrieves hidden information from CGM data could provide a viable method to identify patients with different degrees of dysglycemia and clinical phenotypes.
#cgm
Ascensia Diabetes Care, a leading global diabetes care company, has today entered the continuous glucose monitoring market in Europe as it takes over the distribution of Senseonics’ Eversense® XL, the world’s first and only long-term implantable continuous glucose monitoring (CGM) system, in selected European markets. This follows the signing of a commercialization and distribution agreement in August 2020 with Senseonics Inc., which enables Ascensia to offer Eversense® products, over a 5-year period, in selected countries. As part of this agreement, Ascensia has today taken over distribution of Eversense® XL in Germany, Switzerland, Italy, Spain, The Netherlands and Poland. In the US, Ascensia is already providing sales support for the Eversense® 90-day implantable CGM system, and will take over increased commercialization from April 1, 2021.
#cgm
Former Charlotte Tilbury, Yext exec Alok Bhushan joins Virta on the heels of $1.1 billion valuation